DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) will announce its earnings results after the market closes on Wednesday, November 13th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter. Individual that are interested in registering for the company's earnings conference call can do so using this link.
DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.16) by $0.03. During the same quarter last year, the company posted ($0.16) EPS. On average, analysts expect DiaMedica Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
DiaMedica Therapeutics Trading Down 3.6 %
NASDAQ DMAC traded down $0.16 on Thursday, reaching $4.18. The company's stock had a trading volume of 37,824 shares, compared to its average volume of 49,822. DiaMedica Therapeutics has a 52 week low of $2.12 and a 52 week high of $4.95. The firm has a market cap of $178.48 million, a PE ratio of -8.17 and a beta of 1.46. The business has a 50-day moving average price of $4.26 and a 200 day moving average price of $3.49.
Wall Street Analysts Forecast Growth
Several analysts recently commented on the company. HC Wainwright assumed coverage on DiaMedica Therapeutics in a research note on Monday, October 7th. They issued a "buy" rating and a $7.00 price target on the stock. Oppenheimer reissued an "outperform" rating and issued a $6.00 target price on shares of DiaMedica Therapeutics in a research note on Friday, August 16th.
Check Out Our Latest Research Report on DiaMedica Therapeutics
About DiaMedica Therapeutics
(
Get Free Report)
DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.
Featured Stories
Before you consider DiaMedica Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DiaMedica Therapeutics wasn't on the list.
While DiaMedica Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
